Cornerstone Pharmaceuticals is a US-based, clinical-stage metabolic oncology therapeutics company, dedicated to transforming cancer treatment.

We are pioneering research in altered cancer metabolism, developing first-in-class drugs and drug delivery technologies targeting enzymes within cancer cells’ mitochondria. Our focus is on creating highly selective and effective anti-cancer agents with minimal impact on healthy tissues, representing a significant advancement in cancer therapy.

CPI-613, our lead drug, is currently undergoing Phase I, II, and III clinical trials as a single agent and in combination with standard treatments. We are committed to providing rare science, rare compassion, and rare solutions for patients battling hard-to-treat cancers.

CB-839 (telaglenastat) | Cornerstone Pharmaceuticals

Product description

Cornerstone Pharmaceuticals Cranbury, United States (US)

Price: N/A

Cornerstone Pharmaceuticals
Cranbury, United States (US)